AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Rock Bottom Prices May Tempt Big Pharma
Executive Summary
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.